RDCC Sends Letter to Secretary Robert F. Kennedy Jr. and Trump Administration, Advocating for the Urgent Needs of the Rare Disease Community 

Washington, D.C. – Last week, the Rare Disease Company Coalition (RDCC), on behalf of 29 leading rare disease biotech companies, sent a letter to Department of Health and Human Services Secretary Robert F. Kennedy Jr. and the Trump Administration. The RDCC called on the Administration to prioritize the urgent needs of the 30 million Americans affected by rare disease and support policies that increase innovation and access to life-changing treatments.

The RDCC offers the following policy recommendations to ensure the 1 in 10 Americans living with a rare disease have access to safe and effective therapies:

1. Protect the Rare Disease Incentive Ecosystem
2. Support a Robust Regulatory System to Enable New Innovations
3. Ensure Efficient and Predictable Patient Access to Rare Disease Treatments

The RDCC is ready to serve as a resource to policymakers to create a brighter and healthier future for American families impacted by rare diseases. 

Read the full letter below.